Latest filing published 07 Jun 2023 for Egetis Therapeutics AB (publ), €4,695.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Elisabeth Svanberg: trading record in brief
Elisabeth Svanberg discloses dealings in Egetis Therapeutics AB (publ) to Finansinspektionen. Over a trading history stretching from 6 May 2022 to 5 June 2023, the count stands at 4 filings.
No open-market sale appears; the market trades are 3 purchases worth €24k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant. 2023 to date brings 1 purchase and no sales.
In size, the median ticket on the buying side is €9,502.
On 7 June 2023 came the latest disclosure, an open-market purchase for €4,695 in Egetis Therapeutics AB (publ). The median gap between a trade and its publication by Finansinspektionen is 3 days. The legal deadline for notifying a trade is three business days (MAR article 19). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Elisabeth Svanberg
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,280 shares@ SEK 5.3119.2% of flowAktieISIN SE0003815604FI:csv-83a49feea7200902fb98Canonical exit: 3 Sept 2023 (T+90)
- 27,396 shares@ SEK 3.6548.0% of flowBTA (betald tecknad aktie)FI:csv-9aa8a8c2b72d9e674e63Canonical exit: 16 Aug 2022 (T+90)
- 27,396 shares@ SEK 3.9552.0% of flowBTA (betald tecknad aktie)FI:csv-33c46710c7cb95ade6bfCanonical exit: 16 Aug 2022 (T+90)
- 91,320 shares0Teckningsrätt/UniträttISIN SE0017770019FI:csv-f16498072852e5e60a14
4 of 4 declarations